2012

BioAlliance Pharma announces the registration of Sitavig® in European countries

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the approval of Sitavig® (acyclovir LauriadTM) for the treatment of recurrent labial herpes in 8 European countries*. The decentralized procedure, with Sweden as Reference Member State, ended with a positive opinion for these first 8 countries….read more →

First meeting of the DSMB of the ReLive trial

and continuation without modification of the Phase III clinical trial with Livatag® in primary liver cancer BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces that the European Independent Board of Experts (Data Safety and Monitoring Board, DSMB) held its first meeting on the ReLive…read more →

Quarterly information as of September 30, 2012 • A dynamic progression of BioAlliance Pharma portfolio Orphan

• Orphan Oncology Products: recruitment of the first patients in Phase III clinical trial with Livatag® in primary liver cancer • Specialty Products: signature of a license agreement for Oravig® in the US and preparation for product launch by our partner Vestiq BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products…read more →

New agreement signed for the distribution of Loramyc® in Iran

 with Shafayab Gostar BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the signature of an agreement* with the Company Shafayab Gostar to distribute Loramyc® in Iran (miconazole Lauriad™ mucoadhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients). Under this agreement, Shafayab…read more →

Presentation of Phase I clinical results with AMEP®

biotherapy in the treatment of metastatic melanoma At the European Society for Medical Oncology Congress (ESMO) BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, presented safety and tolerance results of the phase I clinical study with the AMEP® biotherapy in the metastatic melanoma at the…read more →

BioAlliance Pharma announces the execution of its licensing agreement

with Vestiq Pharmaceuticals for Oravig® in the US BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the execution of the licensing agreement with Vestiq Pharmaceuticals to commercialize Oravig® in the United States (known as Loramyc® in Europe) for the treatment of oropharyngeal candidiasis in…read more →

Key milestones and consolidated accounts for the first semester of 2012

• Key achievements in the clinical development programs and especially: – Livatag®: Phase III study opened in France in June 2012, 10 patients already recruited in the study as of August 31, 2012 – Validive™: Expansion of the study to 4 additional European countries, more than 35% of patients recruited with positive feedbacks from the centers • Registration process of…read more →

BioAlliance Pharma announces the grant of US patent covering Sitavig®

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the grant of a US patent protecting its product Sitavig®. This patent covers the Sitavig® tablet, its manufacturing process and its application for the treatment of recurrent labial herpes until 2027. BioAlliance Pharma has conceived and…read more →

BioAlliance Pharma announces a license agreement on Oravig®

In the United States with Vestiq Pharmaceuticals BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces it has signed a binding term sheet with Vestiq for the commercialization rights in the United States of Oravig® (known as Loramyc® in Europe) for the treatment of oropharyngeal…read more →

BioAlliance Pharma extends and strengthens the protection of AMEP®

with the grant of two patents in the US BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces two key achievements in the development of its biotherapy AMEP® with the decision of granting two patents by the USPTO (United States Patent and Trademark Office). AMEP®…read more →

Progress in the development of Loramyc® in Japan

towards its registration by the partner Sosei BioAlliance Pharma SA (Euronext Paris – BIO), an innovation Company dedicated to the development of orphan oncology products and specialty products, has announced today the completion of phase I clinical study with Loramyc® in Japan by its partner Sosei Co., Ltd, in accordance with the development plan established to register the product in…read more →

BioAlliance Pharma reinforces its development team

with the appointment of Louis Kayitalire, MD, as Head of Research and Development BioAlliance Pharma SA (Euronext Paris – BIO), a Company dedicated to orphan oncology products and specialty products, today announces the reinforcement of its development team with the appointment of Louis Kayitalire, MD, as Head of Research and Development. Directly reporting to the CEO, member of the Strategic…read more →

BioAlliance Pharma and Teva announce first license agreement for Sitavig® for Israel

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to oncology orphan products and specialty products today announces the signature of an exclusive license agreement for Sitavig® (Acyclovir Lauriad™) with Abic Marketing Limited (“Teva”), a group subsidiary of Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) for commercialization rights in Israel. BioAlliance Pharma has conceived and developed Sitavig® for the treatment…read more →

Combined Shareholders Meeting

Approval of all the resolutions and Appointment of Thomas Hofstaetter as independent Board Member BioAlliance Pharma SA (Euronext Paris – BIO), a Company dedicated to orphan oncology products and specialty products, announces that its Shareholders’ meeting was held today at its headquarters and has adopted all the resolutions supported by its Board of Directors. Among other decisions, the Shareholders’ meeting…read more →

Receivability of Sitavig® US registration dossier (NDA) for the treatment of recurrent orofacial herpes validated by the FDA

BioAlliance Pharma SA (Euronext Paris – BIO), a Company dedicated to orphan oncology products and specialty products, today announces the receivability of Sitavig® (Sitavir® in Europe) US registration dossier from the Food and Drug Administration(FDA) for the treatment of recurrent orofacial herpes. According to the US registration procedure, the FDA has 60 days from the date of NDA (New Drug…read more →

12